New pill aims to treat anemia in dialysis patients

NCT ID NCT06520826

Ongoing Disease control Sponsor: USRC Kidney Research Source: ClinicalTrials.gov ↗

First seen Mar 14, 2026 · Last updated May 22, 2026 · Updated 7 times

Summary

This study tests the safety of an oral drug called vadadustat, taken three times a week, for treating anemia in adults with end-stage kidney disease who are on hemodialysis. About 2,200 participants will be randomly assigned to receive vadadustat or a standard treatment. Researchers will track hospitalizations and deaths to see if the new dosing schedule is safe.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANEMIA OF CHRONIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Dallas Renal Group

Dallas, Texas, 75230, United States
Nephrology and Hypertension Specialists, PC

Dalton, Georgia, 30720, United States
US Renal Care - Gallup

Gallup, New Mexico, 87301, United States
US Renal Care - Live Oak

Live Oak, Texas, 78233, United States
USRC Kidney Research

Lone Tree, Colorado, 80124, United States

Conditions

Explore the condition pages connected to this study.

ANEMIA OF CHRONIC KIDNEY DISEASE